Document:

exv10w24

Exhibit 10.24

FOREST CITY ENTERPRISES, INC.

Restricted Shares Agreement

          THIS RESTRICTED SHARES AGREEMENT (this “Agreement”) effective as of                     , 2010 is
made by and between Forest City Enterprises, Inc., an Ohio corporation (the “Company”), and the
individual who is named as the Grantee (the “Grantee”) on the signature page of this Agreement.
All capitalized terms have the meanings set forth in the Forest City Enterprises, Inc. 1994 Stock
Plan (As Amended and Restated as of June 19, 2008) (the “Plan”) unless otherwise specifically
provided.

     WHEREAS, the Board of Directors is of the opinion that the interests of the Company and its
shareholders will be advanced by affording present and future executives and key employees an
opportunity to secure stock ownership in the Company; and

     WHEREAS, the execution of a restricted shares agreement substantially in the form hereof has
been authorized by a resolution of the Committee duly adopted on                     , 2010; and

     NOW, THEREFORE, pursuant to the Plan, and subject to the terms and conditions therof and the
terms and conditions hereinafter set forth, the Company hereby confirms to the Grantee, effective
as of                     , 2010 (the “Date of Grant”), the number of Restricted Shares that are shown on
the signature page of this Agreement as the Original Award.

          1. Definitions. All capitalized terms have the meanings set forth in the Plan unless
otherwise specifically provided. As used in this Agreement, the following terms have the following
meanings:

     “Cause” means gross neglect of duty, dishonesty, conviction of a felony,
disloyalty, intoxication, drug addiction, or other similar misconduct adverse to the
best interests of the Company.

     “Change of Control” means if at any time any of the following events has
occurred:

	 	(a)	 	the Company merges itself, or is merged or
consolidated with, another corporation and as a result of such merger
or consolidation less than 51% of the voting power of the
then-outstanding voting securities of the surviving corporation
immediately after such transaction are directly or indirectly
beneficially owned in the aggregate by the former shareholders of the
Company immediately prior to such transaction;
	 
	 	(b)	 	all or substantially all the assets accounted
for on the Consolidated Balance Sheet of the Company are sold or
transferred to one or more corporations or persons, and as a result of
such sale or transfer less than 51% of the voting power of the
then-outstanding voting securities of such corporation or person
immediately after

 

 

	 	 	 	such sale or transfer is directly or indirectly beneficially held in
the aggregate by the former shareholders of the Company immediately
prior to such transaction or series of transactions;
	 
	 	(c)	 	a person, within the meaning of Section 3(a)(9)
or 13(d)(13) (as in effect on the date of the award) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), becomes the
beneficial owner (as defined in Rule 13d-3 of the Securities and
Exchange Commission pursuant to the Exchange Act) of (i) 15% or more
but less than 35% of the voting power of the then-outstanding voting
securities of the Company without prior approval of the Company’s
Board, or (ii) 35% or more of the voting power of the then-outstanding
voting securities of the Company; provided, however,
that the foregoing does not apply to any such acquisition that is made
by (w) any Subsidiary of the Company (x) any employee benefit plan of
the Company or any Subsidiary or (y) any person or group of which
employees of the Company or of any Subsidiary control a greater than
25% interest unless the Board determines that such person or group is
making a “hostile acquisition;”
	 
	 	(d)	 	a majority of the members of the Board are not
Continuing Directors, where a “Continuing Director” is any member of
the Board who (x) was a member of the Board on the date of the award or
(y) was nominated for election or elected to such Board with the
affirmative vote of a majority of the Continuing Directors who were
members of such Board at the time of such nomination or election.

      “Disability” means disability as defined in the Company’s Long Term Disability
Plan, as amended from time to time.

      “Original Award” means the number of Shares indicated as the Original Award on
the signature page of this Agreement.

      “Subsidiary” has the meaning set forth in the Plan, except that for the purpose
of Section 4(b) of this Agreement only, “Subsidiary” shall mean any corporation
(other than the Company) in an unbroken chain of corporations beginning with the
Company if each of such corporations (or a group of corporations that themselves are
Subsidiaries) other than the last corporation in the unbroken chain owns stock
possessing fifty percent or more of the total combined voting power of all classes
of stock in one of the other corporations in such chain.

          2. Issuance of Restricted Shares. The Shares will be treated as issued on the Date of
Grant as fully paid and nonassessable shares and will be represented by certificates registered in
the name of the Grantee and bearing a legend referring to the restrictions set forth in this
Agreement.

2

 

          3. Restriction on Transfer. The Shares may not be transferred, sold, pledged,
exchanged, assigned or otherwise encumbered or disposed of by the Grantee, except to the Company,
until they have become nonforfeitable in accordance with Section 4 of this Agreement. Any
purported transfer, encumbrance or other disposition of the Shares that is in violation of this
Section 3 will be null and void, and the other party to any such purported transaction will not
obtain any rights to or interest in the Shares.

          4. Vesting. (a) The Shares will become nonforfeitable upon the occurrence of the
following:

	 	 	 	 	 
	 	 	Amount Nonforfeitable	 	Date Nonforfeitable
	 

	 	1/4 of the Original Award
	 	On the second anniversary of the Date of
Grant.
	 
	 	 	 	 
	 

	 	1/4 of the Original Award
	 	On the third anniversary of the Date of
Grant.
	 
	 	 	 	 
	 

	 	All Forfeitable Shares
	 	Fourth anniversary of the Date of Grant.

	 	(b)	 	Notwithstanding the provisions of Section 4(a), all of the
Shares will immediately become nonforfeitable if a Change in Control occurs
after the Date of Grant.

               (c) Notwithstanding the provisions of Section 4(a) or Section 5, all of the Shares will
immediately become nonforfeitable if the Grantee:

	 	(i)	 	dies or becomes permanently disabled while in the employ of the
Company or a Subsidiary after the Date of Grant, or
	 
	 	(ii)	 	ceases to be employed by the Company or a Subsidiary due to
Retirement, with the consent of the Committee, of the Grantee, or
	 
	 	(iii)	 	ceases to be employed by the Company or any Subsidiary as the
result of a termination by the employer without Cause.

             5. Termination of Rights and Forfeiture of Shares. Except for Shares that have become
nonforfeitable, all of the Shares will be forfeited if the Grantee ceases to be employed by the
Company or a Subsidiary at any time prior to the fourth anniversary of the Date of Grant. In the
event of a forfeiture, any certificate(s) representing the Shares will be canceled.

             6. Dividend, Voting and Other Rights. Except as otherwise provided in this Agreement,
the Grantee will have all of the rights of a shareholder with respect to the Shares, including the
right to vote the Shares and receive any dividends that may be paid thereon; provided,
however, that any additional Shares or other securities that the Grantee may become
entitled to receive pursuant to a stock dividend, stock split, combination of shares,
recapitalization, merger, consolidation, separation or reorganization or any other change in the
capital structure of the Company will be subject to the same restrictions as the Shares.

3

 

          7. Retention of Stock Certificate(s) by Company. Any certificates representing Shares
will be held in custody by the Company together with a stock power endorsed in blank by the Grantee
with respect thereto, until those Shares have become nonforfeitable in accordance with Section 4.

          8. Agreement Subject to Plan. This Agreement is subject to the provisions of the Plan
and shall be interpreted in accordance therewith. The Grantee hereby acknowledges receipt of a
copy of the Plan.

          9. Compliance with Law. The Company shall make reasonable efforts to comply with all
applicable federal, state and other applicable securities laws with respect to the Restricted
Shares; provided, however, notwithstanding any other provision of this Agreement,
the Company will not be obligated to issue any securities pursuant to this Agreement if the
issuance thereof would result in a violation of any such law.

          10. Withholding Taxes. If the Company shall be required to withhold any federal,
state, local or foreign tax in connection with the vesting of the Shares, and the amounts available
to the Company for such withholding are insufficient, it shall be a condition to delivery of
certificates representing such Shares that the Grantee make provisions that are satisfactory to the
Company for the payment of the balance of such taxes required to be withheld. The Grantee may
elect, pursuant to procedures established by the Company, that all or any part of such withholding
requirement be satisfied by surrendering to the Company of a portion of such Shares. If such
election is made, the shares so retained shall be credited against such withholding requirement at
the Market Value Per Share on the date of such delivery.

          11. Employment Rights. Nothing contained in the Plan or this Agreement shall confer
upon the Grantee any right to be continued in the employment of the Company or any Subsidiary, or
interfere in any way with the right of the Company, or such Subsidiary, to terminate his or her
employment at any time.

          12. Relation to Other Benefits. Any economic or other benefit to the Grantee under
this Agreement will not be taken into account in determining any benefits to which the Grantee may
be entitled under any profit-sharing, retirement or other benefit or compensation plan maintained
by the Company or a Subsidiary and will not affect the amount of any insurance coverage available
to any beneficiary under any insurance plan covering employees of the Company or a Subsidiary.

          13. Severability. In the event that one or more of the provisions of this Agreement
are invalidated for any reason by a court of competent jurisdiction, any provision so invalidated
will be deemed to be separable from the other provisions hereof, and the remaining provisions
hereof will continue to be valid and fully enforceable.

          14. Governing Law. This Agreement is made under, and will be construed in accordance
with, the internal substantive laws of the State of Ohio without regard to conflict of law
principles of such state.

4

 

          15. Restrictive Legends. The Grantee acknowledges that the Shares are subject to the
terms of this Agreement and to transfer restrictions imposed by the securities laws, and that the
certificates representing the Shares will bear a restrictive legend substantially as follows:

	 	 	 	The Shares represented by this certificate were issued pursuant to a
Restricted Shares Agreement effective as of ________, 2010 between Forest
City Enterprises, Inc. and the holder named on the face of this certificate,
and are subject to the terms and conditions, including restrictions on
transfer, of that Agreement. Any purported transfer, encumbrance or other
disposition in violation of that Agreement will be null and void.

          16. Entire Agreement. Subject to Section 8, this Agreement represents the entire
agreement between the Company and the Grantee with respect to these Restricted Shares and
supersedes all prior agreements whether in writing or otherwise.

5

 

     The undersigned Grantee hereby accepts the award of Restricted Shares granted pursuant to this
Agreement, subject to the terms and conditions of the Plan and the terms and conditions set forth
herein.

	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	Name of Grantee	 	 
	 
	 	 	 	 	 	 
	 

	 	Date:	 	 	 	 
	 

	 	 	 	 

	 	 

     Executed in the name and on behalf of the Company at Cleveland, Ohio as of the ___ day of
                    , 2010.

	 	 	 	 	 
	 	FOREST CITY ENTERPRISES, INC.

 	 
	 	By:  	 	 
	 	 	Name:  	Charles A. Ratner 	 
	 	 	Title:  	President and Chief Executive Officer 	 
	 

	 	 	 	 	 
	Date of Grant:                     , 2010
	 	 
	 
	 	 	 	 
	Original Award:

	 	_{#} Restricted Shares
 

	 	 

6exv10w1

Exhibit 10.1

FIRST AMENDMENT

to

AGREEMENT FOR ANTIBODY DISCOVERY AND DEVELOPMENT

This is a first amendment (this “Amendment”) effective as of March 26, 2010 to the Agreement for
Antibody Discovery and Development dated July 25, 2008 related to antibodies to MASP-2 (the
“Agreement”) between Omeros Corporation (“Omeros”), a Washington corporation having an address at
1420 Fifth Avenue, Suite 2600, Seattle, Washington 98101, and Affitech AS (“Affitech”), having an
address at Oslo Research Park, Gaustadalléen 21, N-0349 Oslo, Norway. Unless otherwise defined
herein, all initially-capitalized terms used in this Amendment shall have the same definition as
set forth in the Agreement.

Whereas Affitech has with funding from Omeros generated First Generation Candidate scFv antibodies
(the “Mother Clones”) in accordance with the Agreement and has conducted affinity maturation of the
Mother Clones to yield affinity-matured scFv antibodies (the “Daughter Clones”).

Whereas Omeros has undertaken the costs to have one or more of the Daughter Clones converted by a
third party to one or more full-length IgG formats to produce “IgG Daughter Clones” for further
evaluation.

Whereas Affitech wishes to accelerate the receipt of financial consideration from Omeros under the
Agreement and Omeros wishes to reduce its potential long term financial obligations under the
Agreement.

Therefore, for the above and other consideration, Omeros and Affitech agree that the Agreement is
hereby amended as follows:

	1.	 	Accelerated Payment. Omeros agrees to pay to Affitech the one time sum of five hundred
thousand US dollars (US$500,000) (the “Buy Out Payment”) payable in two payments of two
hundred fifty thousand US dollars (US$250,000) each, with a first payment to be wired to
Affitech by no later than 5:00 pm in Seattle on March 30, 2010 to an account designated by
Affitech and a second payment to be wired to Affitech by no later than 5:00 pm in Seattle on
April 5, 2010 to such account, provided, however, that the parties may mutually agree in
writing to an alternate payment schedule.

	2.	 	Release of Future Payments. In consideration of and effective upon the receipt of the Buy
Out Payment, Affitech hereby releases Omeros from any and all obligation or liability for any
and all payments to Affitech that have not previously been paid under the Agreement,
including, without limitation, the Milestone II Fee, all Development Milestone Payments and
all Sales Royalties.

	3.	 	Release of Development Obligations. Effective upon the receipt of the Buy Out Payment,
Omeros hereby releases Affitech of any and all obligations to complete any additional Services
under the Agreement or to deliver any additional Deliverables under the Agreement. Effective
upon the receipt of the Buy Out Payment, Affitech hereby releases 

 

 

	 	 	Omeros of any and all
obligations to develop and/or commercialize a Final Candidate or any other antibody under the
Agreement. Both Parties shall be excused from further participation in the JAC.

	4.	 	Intellectual Property. The intellectual property provisions set forth in Section 7 of the
Agreement shall remain in full force and effect except that: (a) the Field Exclusivity under
Section 7.4 of the Agreement shall subsist so long as any claim in any patent or patent
application included in the Omeros Pre-existing Intellectual Property related to MASP-2 or in
the New Omeros Intellectual Property remains pending or issued and enforceable; and (b)
Subsection 7.5 concerning limitations in the event of a breach by Omeros of its original
obligation to develop Affitech-Originated MASP-2 Antibodies shall have no further force and
effect. The provisions of Subsection 8.6, concerning Omeros’ right to terminate without cause
and related payment and intellectual property reversion provisions, shall have no further
force and effect.

	5.	 	Additional Representations and Warranties.

	5.1.	 	Affitech hereby acknowledges that the representations and warranties of Section 9.2(b) of the
Agreement shall continue to apply to the Daughter Clones and any IgG Daughter Clones converted
therefrom. Affitech shall provide Omeros with copies of opinion of counsel previously obtained
by Affitech and related to such issues, which Omeros acknowledges shall be covered by the
terms of the Joint Defense Agreement between Affitech and Omeros dated September 8, 2009.

	5.2.	 	Affitech hereby represents and warrants that, to its knowledge, the sequences of the Mother
Clones and the Daughter Clones have not previously been published or publicly disclosed by
Affitech and that the Mother Clones and Daughter Clones have not been made publicly available
by Affitech.

	6.	 	All other terms of the Agreement remain in force and unchanged.

This Amendment is accepted and acknowledged by each Party through the signature of its authorized
representative below:

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	AFFITECH AS	 	 	 	OMEROS CORPORATION	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Martin Welschof	 	 	 	By:	 	/s/ Gregory A. Demopulos	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Martin Welschof, Ph.D.
	 	 	 	 	 	Name:
	 	Gregory A. Demopulos, M.D.	 	 
	 

	 	Title:
	 	Chief Operating Officer
	 	 	 	 	 	Title:
	 	Chairman & CEO	 	 
	 	 	Facsimile: +47 22 95 83 58	 	 	 	 	 	Facsimile: 206 676 5005	 	 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}]]